This guidance recommends bortezomib monotherapy as a possible treatment for progressive multiple myeloma for people:
- whose multiple myeloma has relapsed for the first time after having one treatment, and
- who have had a bone marrow transplant, unless it is not suitable for them.
- After not more than four cycles of treatment, a blood or urine test should be done to check how well the cancer has responded to bortezomib.
- Treatment should be continued only if there has been at least a partial response to the drug.